^
    Back
    Association details:
    Biomarker:PD-L1 expression
    Cancer:Gastroesophageal Cancer
    Drug Class:PD-L1 inhibitor
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    SAGE Journals
    Title:

    The Anti-PD-1/PD-L1 Immunotherapy for Gastric Esophageal Cancer: A Systematic Review and Meta-Analysis and Literature Review

    Published date:
    02/23/2021
    Excerpt:
    Meta-analysis pointed out that in the PD-L1 CPS ≥10 sub group population, the immunotherapy could obviously benefit the patients in tumor response rates (OR = 3.80, 95% CI: 1.89 to 7.61, P = 0.0002)....For the treatment of advanced gastric esophageal cancer, the therapeutic efficacy of anti-PD-1/PD-L1 immunotherapy was superior to that of chemotherapy or palliative care.
    DOI:
    10.1177/1073274821997430